`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Plaintiff,
`
`Defendant.
`
`
`
`
`
`C.A. No. 21-558 (MN)
`
`SHILPA PHARMA, INC.,
`
`
`
`
`
`NOVARTIS PHARMACEUTICALS
`CORPORATION,
`
`
`
`
`
`v.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ORDER ADOPTING REPORT AND RECOMMENDATION
`
`At Wilmington, this 17th day of May 2022:
`
`WHEREAS, on May 5, 2022, Special Master The Honorable Sue L. Robinson issued a
`
`Report and Recommendation (“the Report”) (D.I. 98) in this action recommending that the Court
`
`deny, “without prejudice to renew, e.g., if Mr. Iyer’s role changes contrary to Shilpa’s
`
`representations made to date”, Defendant’s Motion to Disqualify Chidambaram S. Iyer as
`
`Plaintiff’s Counsel Under the Lawyer-Witness Rule (D.I. 41);
`
`
`
`WHEREAS, the Report set a seven (7) day deadline to file written objections such that
`
`objections were due May 12, 2022;
`
`
`
`WHEREAS, no party objected to the shortened objection period and nor did either request
`
`additional time to file objections; and
`
`
`
`WHEREAS, no party filed objections to the Report pursuant to Rule 72(b)(2) of the Federal
`
`Rules of Civil Procedure in the ordered period, and the Court finding no clear error on the face of
`
`the record.
`
`
`
`THEREFORE, IT IS HEREBY ORDERED, that the Report and Recommendation
`
`(D.I. 98) is ADOPTED and Defendant’s Motion to Disqualify Chidambaram S. Iyer as Plaintiff’s
`
`
`
`Case 1:21-cv-00558-MN Document 101 Filed 05/17/22 Page 2 of 2 PageID #: 1022
`
`Counsel Under the Lawyer-Witness Rule (D.I. 41) is DENIED without prejudice to renew, e.g., if
`
`Mr. Iyer’s role changes contrary to Shilpa’s representations made to date.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`The Honorable Maryellen Noreika
`United States District Court Judge
`
`
`
`
`
`2
`
`